Neuromuscular monitoring and the cost of antagonism: when will we learn?

S. J. Brull, R. C. Prielipp

Research output: Contribution to journalLetterpeer-review

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)1557-1558
Number of pages2
JournalAnaesthesia
Volume72
Issue number12
DOIs
StatePublished - Dec 2017

Bibliographical note

Funding Information:
No external funding declared. SB is a member of the Anesthesia Patient Safety Foundation (APSF) Board of Directors (Rochester, MN), has received research funding from Merck & Co., Inc. (Kenilworth, NJ) (funds to Mayo Clinic), is a principal and shareholder in Senzime AB (publ) (Uppsala, Sweden), and a member of the Scientific Advisory Boards for ClearLine MD (Woburn, MA), The Doctors Company (Napa, CA), and NMD Pharma (Aarhus, Denmark). RP is a member of the Anesthesia Patient Safety Foundation (APSF) Executive Committee and Board of Directors (Rochester, MN). Previously posted on the Anaesthesia correspondence website: www.anaes- thesiacorrespondence.com

Cite this